By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Syros Pharmaceuticals 

480 Arsenal Street
Suite 130
Watertown  Massachusetts  02472  U.S.A.
Phone: 617-744-1340 Fax: n/a


We are a therapeutics company passionately committed to applying our scientific leadership in the emerging field of gene control to transform the lives of patients with cancer and other diseases.

Founded by world-leading experts in gene regulation, and led by a seasoned management team, Syros is focused on developing new medicines that control genes that cause disease. Central to our approach is a proprietary drug development platform of integrated gene control assay technologies, computational biology, chemistry, and deep biologic insights that gives us an unprecedented understanding of and control over gene regulation. Our pioneering research and drug development capabilities provide us with the distinctive ability to identify new, important disease and patient-targeted gene control medicines.

Key Statistics

Ownership: Private

Web Site: Syros Pharma


Company News
Syros Pharma Reports Fourth Quarter And Full Year 2016 Financial Results And Highlights Key Accomplishments And Upcoming Milestones 3/20/2017 6:52:57 AM
Syros Pharma Reports Discovery Of Novel Genomics Based Approach To Stratifying Patients With Acute Myeloid Leukemia At Cold Spring Harbor Conference 2/27/2017 6:36:01 AM
Syros Pharma’ Drug Discovery Research In Immuno-Oncology Highlighted At University of California, San Diego (UCSD) Moores Cancer Center Symposium 2/21/2017 8:24:22 AM
Syros Pharma Announces Publication In Cell Highlighting Gene Control As Important And Rapidly Progressing Area Of Research For Yielding New Medicines To Treat Cancer 2/10/2017 7:13:58 AM
Syros Pharma Appoints Industry Leader Peter Wirth As Chair Of Its Board Of Directors 1/30/2017 9:09:34 AM
Syros Pharma Announces 2017 Strategic Priorities And Goals 1/9/2017 11:11:16 AM
Syros Pharma Presents New Preclinical Data Demonstrating Significant Anti-Proliferative Effects Of Its First-in-Class Selective RARa Agonist In Genomically Defined Subsets Of Breast Cancer 12/12/2016 10:47:47 AM
Syros Pharma Presents Data At American Society of Hematology Annual Meeting Further Supporting Clinical Potential Of Its First-In-Class Selective Rara Agonist For Genomically Defined Subsets Of AML And MDS Patients 12/5/2016 11:27:01 AM
Syros Pharma Reports Third Quarter 2016 Financial Results And Provides Business Update 11/14/2016 11:46:20 AM
Syros Pharma Announces Approval Of Investigational Device Exemption (IDE) For Blood Test To Identify Cancer Patients With Proprietary Biomarkers 10/11/2016 11:07:59 AM